FDA delays decision on Intercept's liver drug; Alimera reportedly up for sale;

@FierceBiotech: 'Lies, deceit and greed': Martin Shkreli blasted by the feds for Ponzi scheme. More | Follow @FierceBiotech

@JohnCFierce: AstraZeneca hit with another setback as durvalumab disappoints on lung cancer. Report | Follow @JohnCFierce

@DamianFierce: Hear me out: José Mourinho for  CEO. | Follow @DamianFierce

> The FDA extended its review of Intercept Pharmaceuticals' ($ICPT) treatment for primary biliary cirrhosis, adding three months to a process that was previously to conclude on Feb. 29. News

> Alimera Sciences ($ALIM) is looking into selling itself, Reuters reports. Story

> Ariad Pharmaceuticals ($ARIA) appointed Merck KGaA executive Paris Panayiotopoulos to serve as its next CEO, replacing founder Harvey Berger effective Jan. 1. More

> Merck ($MRK) is expecting to win European approval for its hepatitis C combination treatment by mid-2016. The company is in line for FDA approval by Jan. 28. Item

Medical Device News

@FierceMedDev: VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report | Follow @FierceMedDev

@EmilyWFierce: Toxin from sea algae impacts memory, behavior in California sea lions: Study. FierceAnimalHealth story | Follow @EmilyWFierce

> FDA approves Zoll's wearable defibrillator for use in children. More

> Gelesis drops IPO, raises $31.5M for pivotal U.S. trial of hydrogel weight-loss capsule. Story

> Philips' Volcano to keep Sacramento site despite 60 manufacturing layoffs. Article

Pharma News

@FiercePharma: Drug costs soar as China tops world ranking in cancer. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Will prosecutors recommend 5000% increase in jail time in specific cases of pharma securities fraud? More | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire prepared to walk on Baxalta talks if deal doesn't come soon: WSJ. Story | Follow @CarlyHFierce

> U.S. shells out more for top-selling drugs, even when rebates are factored in: Bloomberg. More

> EMA warns of PML, cancer risks from Novartis' Gilenya. Story

> Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.